argenx stock: ACR Convergence sets next clinical catalyst

argenx is heading into a week that puts its autoimmune myositis program in front of the rheumatology community. ACR Convergence 2026 begins on Friday, November 6, in Orlando, while the company's Phase 3 ALKIVIA results are scheduled for a late-breaking oral presentation on Wednesday, November 11.

In a press release dated October 19, argenx said the ALKIVIA study met its primary endpoint. In the combined immune-mediated necrotizing myopathy and dermatomyositis population, efgartigimod delivered a 15.4-point greater improvement in mean Total Improvement Score than placebo at Week 52. The reported scores were 47.95 versus 32.56, with a p-value of 0.0011.

ALKIVIA data set the next catalyst

The presentation is titled "Efgartigimod PH20 SC in Adults With Idiopathic Inflammatory Myopathy: Results From the Phase 3, Randomized, Placebo-Controlled ALKIVIA Trial" and is listed as session LB24. Lead author Dr. Rohit Aggarwal is scheduled to present the data from 9:15 to 9:30 a.m. Eastern Time.

argenx said improvements in disease activity emerged as early as Week 4 and continued through 52 weeks, including during steroid tapering. The company also reported that efgartigimod was well tolerated in the study, with a safety profile consistent with earlier studies and its known profile. The readout matters because autoimmune myositis remains an area with limited targeted treatment options, particularly for immune-mediated necrotizing myopathy.

argenx stock traded at 801.30 euros on Lang & Schwarz at 17:09 CET on Sunday, November 1, 2026. Investors can follow the real-time quote of argenx stock.

European biotechnology shares will remain sensitive to clinical readouts and regulatory signals; the AEX market environment provides the broader regional backdrop.

For further coverage, see more news and analyses on argenx stock.